Please login to the form below

Not currently logged in
Email:
Password:

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

Pfizer AstraZeneca 

With big pharma companies seemingly intent on slimming down at the moment, the rumour that Pfizer is looking to acquire AstraZeneca (AZ) in a $101bn deal seems like a step back in time.

If confirmed, the deal would be much bigger than any consummated in the late 1990s and 2000s, including Pfizer's own $68bn acquisition of Wyeth in 2009, the $74bn merger that created GlaxoSmithKline (GSK) in 2000 and the $56bn acquisition of Pharmacia by Pfizer in 2002.

A report in the Sunday Times suggests that talks between the two companies were actually held several months ago but have lapsed, adding that Pfizer is likely to try a hostile attempt as AZ resisted its initial overture. Meanwhile, other commentators have been quick to point out the merits of the deal.

Pfizer would be able to tap into a reinvigorated AZ pipeline that has been bolstered with a series of licensing deals and acquisitions in the last couple of years, including the recent purchase of rights to a diabetes franchise formerly co-owned with Bristol-Myers Squibb (BMS) and a well-regarded cancer pipeline that includes a number of immunotherapies.

For its part, the US drug major has a large pipeline - although it lacks candidates with big sales potential - and has a stated ambition to boost its position in oncology.  The merger could also provide an opportunity for Pfizer to invest its approximately $70bn in cash reserves outside the US and reduce its tax burden and provide significant cost-saving opportunities.

Meanwhile, Pfizer has started to emerge from a patent cliff while AZ is still facing expirations on key earners such as gastrointestinal therapy Nexium (esomeprazole) and cholesterol-lowerer Crestor (rosuvastatin).

Analyst Andrew Baum of Citi said in a research note yesterday he expects Pfizer to "push aggressively" for a merger, while there is already speculation that the publicity surrounding the negotiation will flush out other potential suitors, including Novartis and GSK, that have been linked with AZ in the recent past.

It has been argued that mega-mergers have been an exercise in destroying value in the pharma sector, with the challenges and disruption associated with bringing together two corporations outweighing the effect of combining pipelines, increased marketing muscle and cost-savings.

However, a recent report from McKinsey & Co turned that viewpoint on its head, suggesting that at least in terms of shareholder value and profits mega-mergers worked and - in some cases - were critical for the long-term sustainability of the acquiring companies.

Article by
Phil Taylor

22nd April 2014

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....